Vertex and Amazon Poised for Growth, Likely to Outperform Market
-
Vertex Pharmaceuticals has a successful cystic fibrosis drug franchise and pipeline of potential new blockbusters for other diseases. Its stock price has risen 40% in the past year.
-
Amazon's core e-commerce business proved resilient despite economic uncertainty. Its fast-growing advertising and cloud computing units boost profits.
-
Vertex is developing treatments for diseases lacking options, including a landmark approved gene-editing therapy for blood disorders.
-
Amazon accounts for 13% of US digital ad revenue and 10% globally, gaining market share in the massive ad market.
-
Both Vertex and Amazon are quality businesses poised for long-term growth, making them stocks likely to crush the market in 2024 and beyond.